# Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer

> **NCT02083653** · PHASE2 · COMPLETED · sponsor: **Symphogen A/S** · enrollment: 254 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Sym004 (12 mg/kg)
- **DRUG:** Sym004 (9/6 mg/kg)
- **OTHER:** Best Supportive Care (BSC)
- **DRUG:** Fluorouracil (5-FU)
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT02083653
- **Lead sponsor:** Symphogen A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03-06
- **Primary completion:** 2016-10-24
- **Final completion:** 2017-04-26
- **Target enrollment:** 254 (ACTUAL)
- **Last updated:** 2019-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02083653

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02083653, "Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02083653. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*